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Dantrolene sodium was well tolerated by Wolfram syndrome patients. Overall, β cell functions were not significantly
improved, but there was a significant correlation between baseline β cell functions and change in β cell responsiveness
(R2, P = 0.004) after 6-month dantrolene therapy. Visual acuity and neurological functions were not improved by 6-month
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Introduction
Wolfram syndrome is an ultrarare, progressive neurodegenerative disorder characterized by juvenile-onset insu-
lin-requiring diabetes mellitus and optic nerve atrophy (1, 2). Other clinical manifestations of Wolfram syn-
drome include diabetes insipidus, deafness, neurogenic bladder, and ataxia. Most individuals with Wolfram 
syndrome have a shortened life span due to severe neurological disabilities caused by brainstem and cerebellar 
BACKGROUND. Wolfram syndrome is a rare ER disorder characterized by insulin-dependent diabetes 
mellitus, optic nerve atrophy, and progressive neurodegeneration. Although there is no treatment for 
Wolfram syndrome, preclinical studies in cell and rodent models suggest that therapeutic strategies 
targeting ER calcium homeostasis, including dantrolene sodium, may be beneficial.
METHODS. Based on results from preclinical studies on dantrolene sodium and ongoing 
longitudinal studies, we assembled what we believe is the first-ever clinical trial in pediatric 
and adult Wolfram syndrome patients with an open-label phase Ib/IIa trial design. The primary 
objective was to assess the safety and tolerability of dantrolene sodium in adult and pediatric 
Wolfram syndrome patients. Secondary objectives were to evaluate the efficacy of dantrolene 
sodium on residual pancreatic β cell functions, visual acuity, quality-of-life measures related to 
vision, and neurological functions.
RESULTS. Dantrolene sodium was well tolerated by Wolfram syndrome patients. Overall, β cell 
functions were not significantly improved, but there was a significant correlation between baseline 
β cell functions and change in β cell responsiveness (R2, P = 0.004) after 6-month dantrolene 
therapy. Visual acuity and neurological functions were not improved by 6-month dantrolene 
sodium. Markers of inflammatory cytokines and oxidative stress, such as IFN-γ, IL-1β, TNF-α,  
and isoprostane, were elevated in subjects.
CONCLUSION. This study justifies further investigation into using dantrolene sodium and other 
small molecules targeting the ER for treatment of Wolfram syndrome.
TRIAL REGISTRATION. ClinicalTrials.gov identifier NCT02829268
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(TR002065, TR000448), NIH training grant (F30DK111070), Silberman Fund, Ellie White Foundation, 
Snow Foundation, Unravel Wolfram Syndrome Fund, Stowe Fund, Eye Hope Foundation, Feiock 
Fund, Washington University Institute of Clinical and Translational Sciences grant UL1TR002345 
from NIH/NCATS, Bursky Center for Human Immunology & Immunotherapy Programs.
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atrophy (3). There has yet to be a treatment devised that has been shown to provide a cure or slow the insidious 
progression of this disease. As a result, patients with Wolfram syndrome are currently only offered therapies 
aimed at treating each aspect of the disease individually.
Since the discovery of  Wolfram syndrome 1 gene (WFS1) as the causative locus for most cases of  Wol-
fram syndrome, research efforts have sought to understand the underlying etiology of  this disorder. Our 
current understanding is that Wolfram syndrome is a prototype of  ER disease in humans (4). WFS1 is a 
multipass ER transmembrane protein with an established role in the negative regulation of  ER stress and the 
maintenance of  cellular calcium homeostasis (5, 6). While the molecular details of  WFS1 function require 
further study, it is clear that pancreatic β cells and neurons are particularly affected by, and perhaps especially 
sensitive to, disease-causing WFS1 genetic variants. Indeed, previous reports from our lab identified calcium 
dyshomeostasis as a key mechanism underlying pancreatic β cell and neuronal cell death in the context of  
WFS1 depletion (7–9). These preclinical studies led to identifying dantrolene sodium as a potential therapeu-
tic candidate for restoring ER calcium homeostasis and mitigating the progression of  Wolfram syndrome.
Dantrolene sodium is a hydantoin derivative skeletal muscle relaxant whose mechanism of  action 
revolves around the inhibition of  ryanodine receptors (RyRs) on the ER (10–12). Although the mechanism 
of  action of  dantrolene remains unclear, its effects are well-documented. Dantrolene inhibits ER calcium 
efflux through RyRs, thereby reducing cytosolic calcium and preserving ER calcium (13). The primary 
indication for dantrolene is in the treatment of  malignant hyperthermia, which can be an adverse reac-
tion to general anesthesia and is FDA approved for use in both adults and children. Dantrolene has also 
been used off-label for the treatments of  spasticity disorders and cerebral vasospasm (14, 15). Interestingly, 
recent studies have proposed a potential role for dantrolene sodium as a treatment for neurodegenerative 
disorders, such as Huntington’s disease (16), spinocerebellar ataxia (17, 18), and Alzheimer’s disease (19, 
20), where ER calcium may play a pivotal role in disease pathogenesis.
We showed positive preclinical results in mouse and induced pluripotent stem cell (iPSC) models of  
Wolfram syndrome treated with dantrolene sodium before (8). Based on those results, our group put togeth-
er what we believe is the first-ever clinical trial in subjects with Wolfram syndrome. Our research team was 
particularly sensitive to the unique challenges of  performing a clinical trial for a disease as rare as Wolfram 
syndrome (21). These challenges include the small numbers of  subjects available to study and the vast 
heterogeneity of  symptoms exhibited by patients with Wolfram syndrome (22). Multiple stakeholders were 
involved in the design of  this clinical trial, including I-TRAK (a natural history study of  neurodegeneration 
in early Wolfram syndrome, ClinicalTrials.gov NCT03951298) and various Wolfram syndrome patient/
parent advocacy groups because they would be likely sources for recruitment. After these collaborations, an 
open-label phase Ib/IIa trial design was chosen. The primary endpoint of  the study was to assess the safety 
and tolerability of  dantrolene sodium in adult and pediatric subjects with Wolfram syndrome. Secondary 
objectives were to assess the effect of  dantrolene sodium on residual pancreatic β cell function, visual acui-
ty, neurological function, and quality-of-life measures.
Results
Trial population
A total of  22 subjects (6–32 years old), with a genetically confirmed diagnosis of  Wolfram syndrome, were 
screened for enrollment in this study (Figure 1, A and B). Of  this group, 21 qualified for baseline labo-
ratory and quality-of-life assessments in order to begin the run-in regimen of  oral dantrolene parallel to 
ongoing maintenance medications. Two subjects (11% of  qualified population) had to be excluded before 
the 6-month assessment of  study outcome measures on dantrolene treatment due to loss to follow-up or 
personal reasons. The baseline demographics and clinical characteristics of  the 19 subjects who complet-
ed the trial are shown in Table 1. The subjects or their parents made the classifications of  demographics. 
Subject-specific WFS1 mutations and clinical data are summarized in Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.145188DS1. The baseline 
therapies the subjects took are shown in Supplemental Table 2. At enrollment 100% of  subjects carried a 
diagnosis of  diabetes mellitus. However, only 63% of  pediatric subjects and 100% of  adult subjects carried 
a diagnosis of  optic atrophy. This pattern is consistent with the documented natural history of  Wolfram 
syndrome, where juvenile-onset diabetes mellitus typically manifests within the first decade, followed by 
optic atrophy in the second decade of  life (3, 23, 24).
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Safety outcomes
Dantrolene was well tolerated among pediatric subjects at a final daily dose between 0.5 mg/kg and 2.0 mg/kg, 
with a maximum daily dose of 100 mg. The mean final daily dose in the pediatric subjects was 1.25 mg/kg/d 
(Figure 1C). Adult subjects tolerated dantrolene well between 50 mg and 100 mg daily. Respectively, 5, 4, and 2 
subjects tolerated 50, 75, and 100 mg of dantrolene. This resulted in a mean dose of 68.2 mg daily (Figure 1D). 
These dosing ranges closely approximated therapeutic ranges for dantrolene when used to treat spasticity (25).
Adverse events were stratified into 3 categories based on their likelihood of  being attributed to the study 
drug. These categories included adverse events attributed directly to dantrolene, events known to occur 
commonly in patients with Wolfram syndrome, and nonspecific events not easily attributed to dantrolene 
or Wolfram syndrome. The most common adverse dantrolene-related events observed in pediatric and 
adult subjects were mild fatigue and diarrhea. The most common Wolfram syndrome–related events were 
mild hypoglycemia and headaches. These symptoms affected at least 25% of  the total study population 
(Table 2). Hepatotoxicity and weakness, the most serious known side effects of  dantrolene, were not very 
Figure 1. Trial design, enrollment, and retention. (A) Enrollment and retention diagram for the subjects enrolled in the study. (B) Schematic of 6-month 
study. Each study visit is noted by a black circle. Study procedures for secondary endpoints are noted in blue. The dose maximization period for dantrolene 
sodium is noted by the red dashed lines. HbA1c, hemoglobin A1c; MMTT, mixed meal tolerance test; WURS, Wolfram Unified Rating Scale. (C) Histogram 
demonstrating distribution of final tolerated dantrolene doses in pediatric subjects at the end of the study. For pediatric subjects this is expressed as mg/
kg/d. (D) Histogram demonstrating distribution of final tolerated dantrolene doses in adult subjects at the end of the study. For adult subjects this is 
expressed as mg/d. For both histograms the blue bars represent numbers of subjects taking a dose.
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prevalent in our study population. Elevated liver enzymes were observed in 2 subjects (11% of  total popu-
lation), and weakness was self-reported by 4 subjects (21% of  total population). Quantitative assessments 
of  strength prior to and at each subsequent trial visit after dantrolene administration showed no signifi-
cant loss in grip strength during 6 months of  dantrolene treatment (Supplemental Figure 1). No clinically 
significant changes in laboratory measures or in findings from physical examinations were noted during 
enrollment in this study. No significant ECG changes were observed in subjects during the run-in period or 
thereafter. Additionally, no subject discontinued the trial regimen due to adverse effects.
Secondary outcomes
Markers of  β cell function. To assess the effect of  dantrolene on glycemia and remaining β cell function, HbA1c 
and 30-minute mixed meal stimulated C-peptide were monitored at baseline and after 6 months of  dantro-
lene treatment (Figure 1B). Mean HbA1c across all subjects remained stable between dantrolene initiation 
and after 6 months of  treatment (7.4% ± 0.2%, P value 0.63) (Table 3). Subgroup analyses of  adult and 
pediatric subjects also demonstrated no significant change in HbA1c (7.4% ± 0.2%) (Table 4). Mean fasting 
C-peptide levels of  the total study cohort also remained stable during this period (0.27 ± 0.07 ng/mL at 6 
months of  treatment compared to 0.27 ± 0.06 ng/mL at baseline, P value 0.95) (Table 3). At the conclusion 
of  the study, mean stimulated C-peptide levels were not significantly higher compared to the pretreatment 
baseline (0.64 ± 0.14 ng/mL after 6 months of  treatment compared to 0.52 ± 0.10 ng/mL at baseline, P 
value 0.14) (Table 3). Supplemental Figure 2 demonstrates subject-specific change in fasting and stimulated 
C-peptide over the 6-month study period. When looking at all subjects, ΔC-peptide (the change in C-peptide 
between 0 and 30 minutes) was not significantly increased. Mean ΔC-peptide was 0.37 ± 0.07 ng/mL after 6 
months of  treatment, compared to 0.25 ± 0.04 ng/mL at baseline (P value 0.18) (Table 3).
Additional markers of β cell function were assessed, including measuring proinsulin along with C-peptide 
during the mixed meal tolerance testing. Insulinogenic index (26) and AUC C-peptide/AUC glucose (27) were 
calculated for each study subject. No significant differences were found in any of these categories (Tables 3–5).
Subgroup analyses. Additional subgroup analysis was performed in the study population to determine if  
there was a subset of  subjects who had the most beneficial response to dantrolene. Our hypothesis was that 
subjects who possessed the greatest degree of  β cell function at baseline would have the greatest glycemic 
benefit from dantrolene. Therefore, we examined the change in ΔC-peptide (ΔΔC-peptide) over the course 
of  the study to approximate changes in β cell responsiveness. ΔΔC-peptide was calculated by subtracting 
the ΔC-peptide at baseline from the ΔC-peptide at 6 months. To test our hypothesis, we divided the sub-
jects based on increasing cutoffs of  ΔΔC-peptide (<0.05, 0.05–0.1, and >0.1 ng/mL). We noted that 5 
subjects had a ΔΔC-peptide ≥ 0.1 ng/mL, 4 subjects had a ΔΔC-peptide 0.05–0.1 ng/mL, and 6 subjects 
had a ΔΔC-peptide < 0.05 ng/mL. The remaining subjects were missing data necessary for calculation of  
ΔΔC-peptide because we could not perform the MMTT due to their high fasting blood glucose levels (Figure 
2A and Figure 3A). Review of  these data suggested that our hypothesis was correct, as subjects with higher 
ΔC-peptide to begin with tended to have a higher ΔC-peptide at 6 months and higher slope (ΔΔC-peptide). 
Table 1. Demographic and clinical characteristics of the study subjects
Characteristic Pediatric (n = 8) Adult (n = 11)
Median age (range), y 13 (6–17) 23 (18–32)
Female sex, no. (%) 6 (75) 8 (73)
Male sex, no. (%) 2 (25) 3 (27)
BMI (range), kg/m2 20.3 (15.3–29.3) 27.0 (17.8–48.9)
Race/ethnicity, no. (%)
 Caucasian
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To further test this relationship, we performed linear regression analysis, demonstrating a statistically signif-
icant (R2 0.439, P value 0.004) positive relationship between baseline ΔC-peptide and ΔΔC-peptide (Figure 
2B). Based on previous literature (28, 29), we decided that the cutoff  of  a ΔΔC-peptide ≥ 0.1 ng/mL is 
likely to be of  clinical significance for subjects with Wolfram syndrome. This fit the overall distribution of  
data, as 5 subjects (subject ID 4, 8, 10, 17, and 22) met this criterion. They represented 26.3% of  the total 
study population. These subjects included 3 adult and 2 pediatric individuals. The ΔΔC-peptide ≥ 0.1 ng/
mL cutoff  was henceforth used to classify subjects as responders versus nonresponders.
There were no significant differences between responders and nonresponders in terms of  HbA1c at 
the beginning (7.1% ± 0.2% and 7.5% ± 0.2%, respectively, P value 0.49) of  the study and after 6 months 
of  treatment (7.1% ± 0.3% and 7.6% ± 0.3%, respectively, P value 0.42) (Table 5). Prior to treatment with 
dantrolene, responder subjects had higher fasting C-peptide compared with nonresponders (0.47 ± 0.17 
ng/dL compared with 0.18 ± 0.03 ng/dL, P value 0.03). By design, responder subjects demonstrated sta-
tistically significant increases in fasting C-peptide (0.53 ± 0.17 ng/dL to 0.15 ± 0.006 ng/dL), stimulated 
C-peptide (1.20 ± 0.33 ng/dL to 0.38 ± 0.05 ng/dL, P value 0.003), and ΔC-peptide (0.67 ± 0.17 ng/dL to 
0.23 ± 0.02 ng/dL, P value 0.002) after the 6-month treatment period (Table 5). There were no significant 
differences between responders and nonresponders in terms of  C-peptide/glucose ratios (Supplemental 
Figure 3 and Supplemental Table 3).
Markers of  visual acuity. To evaluate the effect of  dantrolene treatment on visual acuity and vision-related 
quality of  life, participants underwent ophthalmologic examination at screening, at baseline, and after 6 
months of  dantrolene treatment. No significant changes in visual acuity were observed across subjects or 
age groups as a function of  dantrolene treatment (Figure 3B and Tables 3–5). Of  note, subject 12 had a 
LogMAR = 3 throughout the study period, which equates to functional blindness. As a result, subject 12’s 
data were excluded from analysis. Supplemental Figure 4 demonstrates the LogMAR data including subject 
12. Subgroup analyses did not identify any significant differences between adult and pediatric subjects or 
subjects deemed nonresponders or responders. Correspondingly, subjects reported no significant improve-
ments in vision-related quality of  life as measured by the National Eye Institute’s 25-item Visual Function 
Questionnaire (NEI VFQ-25) (Supplemental Table 4).
Table 2. Adverse events during the study
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Linear regression analysis was performed comparing ΔΔC-peptide with LogMAR. This resulted in a 
slight, but statistically significant, negative correlation (R2 0.136, P value 0.023) (Supplemental Figure 5A).
Disease severity and quality of  life. Overall disease severity was assessed in subjects prior to and 6 months 
after starting dantrolene treatment via WURS assessment (30). There were no differences in total WURS 
disease severity, or mean physician-rated physical exam scores, across the 6 months of  the study (Figure 3, C 
and D, and Tables 3–5). Similarly, pediatric subjects displayed no significant changes in physical or psycho-
social health domains as measured by the Pediatric Quality of  Life Inventory (PedsQL) between screening 
and 6 months of  dantrolene therapy (Supplemental Table 5), and adult subjects did not show differences in 
physical or mental health metrics when assessed by the SF-36v2 (Supplemental Table 6).
Similar to the LogMAR data, linear regression analysis was performed correlating ΔΔC-peptide to total 
WURS and physician-rated WURS. These regression plots appeared to demonstrate a negative correlation 
but did not reach statistical significance (R2 0.085, P value 0.117 and R2 0.021, P value 0.444, for total WURS 
and physician-rated WURS, respectively) (Supplemental Figure 5, B and C).
Exploratory biomarker levels. It has been shown that ER stress induces sterile inflammation and oxidative 
stress (31–33). Therefore, we assessed expression levels of  inflammatory cytokines and isoprostane, an estab-
lished marker of  oxidative stress in study subjects prior to and 6 months after starting dantrolene treatment via 
WURS assessment (34–36) (Supplemental Table 7). As compared with levels previously reported in heathy 
subjects (35–37), levels of  IFN-γ, TNF-α, IL-1β, MIP-1β, MIP-3α, IL-21, and isoprostane were higher in study 
subjects with Wolfram syndrome. Among those, a statistically significant decrease in IL-1β and IL-21 levels 
was seen after 6 months of  treatment with dantrolene sodium.
Discussion
In this study, we evaluate the safety and tolerability of  dantrolene sodium as a therapeutic approach for Wol-
fram syndrome. Our previous preclinical studies showed that dantrolene improves β cell and neuronal cell 
survival in mouse and patient iPSC models of  this disease (8). To translate these findings to humans, we con-
ducted the first clinical trial in pediatric and adult subjects with Wolfram syndrome in a 6-month study of  dan-
trolene sodium (NCT02829268). We identified a tolerable range of  oral dantrolene dosing of  0.5 mg/kg/d to 
2 mg/kg/d for pediatric subjects and 50 mg/d to 100 mg/d for adults. We did not find any significant changes 
in their baseline medications or drug interaction that might affect the efficacy. Overall, dantrolene was very 
well tolerated, and aside from mild fatigue and diarrhea, no clinically significant adverse events were reported.
Admittedly, this proof-of-concept study ran into many of  the same issues that plague early clinical trials 
for rare diseases (21). As the incidence of  Wolfram syndrome is so rare, it is difficult to recruit a large enough 
sample size in order to detect a statistically significant difference in secondary measures of  β cell function, 
Table 3. Secondary study endpoints for all subjects
Duration (months) 0 SEM 6 SEM P value
HbA1c (%) 7.4 0.2 7.4 0.2 0.88
Fasting glucose (mg/dL) 145.5 9.4 165.3 16.2 0.30
Stimulated glucose (mg/dL) 243.3 12.5 263.8 13.3 0.27
ΔGlucose (mg/dL) 97.8 9.7 98.6 7.5 0.95
Fasting C-peptide (ng/mL) 0.27 0.06 0.27 0.07 0.98
Stimulated C-peptide (ng/mL) 0.52 0.10 0.64 0.14 0.50
ΔC-peptide (ng/mL) 0.25 0.04 0.37 0.07 0.18
Fasting proinsulin (pmol/L) 0.8 0.2 1.0 0.3 0.60
Stimulated proinsulin (pmol/L) 1.6 0.5 2.7 0.9 0.31
ΔProinsulin (pmol/L) 0.8 0.3 1.7 0.7 0.24
Insulinogenic index 0.003 0.001 0.005 0.002 0.112
AUC C-peptide/AUC glucose 0.002 0.000 0.002 0.000 0.994
BMI (kg/m2) 24.5 1.7 24.2 1.9 0.94
LogMAR 0.7 0.2 0.8 0.2 0.90
WURS 20.8 3.0 18.5 3.4 0.61
WURS (physician rated) 5.8 1.3 6.4 1.7 0.78
ΔC-peptide, the change in C-peptide between 0 and 30 minutes; LogMAR, a measure of visual acuity.
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visual acuity, or quality of  life. To aid with recruitment, our study team collaborated with existing natural 
history studies and patient organizations. Another challenge facing this study is the vast clinical heterogene-
ity seen in the spectrum of  individuals with Wolfram syndrome (38). Independent of  age, some individuals 
are more severely affected or progress more rapidly than others. Our hypothesis is that these differences may 
be based on the severity of  the WFS1 gene variants. For example, individuals with missense pathogenic vari-
ants may have a less severe course compared with individuals with large deletions or nonsense pathogenic 
variants. This clinically and genetically heterogeneous population makes it more challenging to infer cause-
and-effect relationships when studying a potential drug. As a result, our strategy has been to target the under-
lying cellular defect (ER calcium depletion) that is unified among all patients with Wolfram syndrome (39).
With the above challenges in mind, there remain additional shortcomings of  this study. As it is an uncon-
trolled study, certain parameters measured are susceptible to confounding by the placebo effect. Due to the 
small sample sizes, there were no statistically significant differences in β cell function or disease severity. For 
these reasons, this study does not posit that dantrolene improves β cell function or disease severity. Instead, 
it identifies safe doses for treatment of  adult and pediatric subjects with Wolfram syndrome, highlights the 
side effect profile of  dantrolene in this population, and argues that further investigation of  dantrolene, or 
investigational agents with a similar mechanism of  action, are warranted in a randomized, double-blind, 
placebo-controlled study. With this caveat in mind, this study also suggests that dantrolene requires further 
investigation in the context of  β cell function and neurodegeneration.
Perhaps the most salient question arising from this study is whether dantrolene improves human β cell 
function in Wolfram syndrome. While a controlled human study is required to assess dantrolene’s efficacy at 
improving β cell function, pediatric subjects in our study started to exhibit a trend toward higher stimulated 
C-peptide levels after 6 months of  sustained dantrolene treatment. Adult subjects, in contrast, showed a 
negligible increase in mean stimulated C-peptide levels throughout their duration of  dantrolene treatment. 
These data suggest that dantrolene may be more effective in pediatric subjects, possibly because these sub-
jects have a larger surviving subpopulation of  functional β cells during this initial phase of  their disease 
process. Evidently, adult subjects also secrete very low levels of  insulin, but dantrolene did not seem to sig-
nificantly enhance β cell function in this group.
The significance of these small elevations in C-peptide is quite interesting when comparing Wolfram syn-
drome with type 1 diabetes. Recently, there has been a growing body of literature suggesting that there is clinical 
benefit from a very small degree of residual β cell function. Oram and colleagues published a population-based 
study in the United Kingdom, demonstrating that 8% of subjects had a urinary C-peptide/creatinine ratio 
≥ 0.2 nmol/mmol (29). This study and another follow-up study in 2019 demonstrated that this persistent 
microsecretion of C-peptide is associated with fewer complications of diabetes and less hypoglycemia (28). 
Table 4. Secondary study endpoints for all pediatric and adult subjects
Class Adult Pediatric
Duration (months) 0 SEM 6 SEM P value 0 SEM 6 SEM P value
HbA1c (%) 7.4 0.2 7.4 0.3 0.94 7.4 0.4 7.6 0.4 0.77
Fasting glucose (mg/dL) 140.4 13.6 161.5 23.4 0.45 154.0 11.1 171.5 21.2 0.48
Stimulated glucose (mg/dL) 223.6 12.9 255.9 18.4 0.17 276.2 20.0 277.0 18.3 0.98
ΔGlucose (mg/dL) 83.2 11.3 94.4 10.9 0.48 122.2 13.5 105.5 8.8 0.32
Fasting C-peptide (ng/mL) 0.21 0.06 0.20 0.06 0.94 0.37 0.14 0.39 0.12 0.92
Stimulated C-peptide (ng/mL) 0.40 0.10 0.50 0.17 0.61 0.71 0.21 0.86 0.25 0.65
ΔC-peptide (ng/mL) 0.19 0.05 0.30 0.09 0.29 0.34 0.07 0.47 0.13 0.38
Fasting proinsulin (pmol/L) 0.6 0.1 1.0 0.3 0.24 1.0 0.5 1.2 0.6 0.16
Stimulated proinsulin (pmol/mL) 1.1 0.3 2.1 1.2 0.31 2.4 1.2 3.9 1.5 0.83
ΔProinsulin (pmol/L) 0.5 0.3 1.1 0.9 0.36 1.4 0.7 2.7 1.1 0.55
Insulinogenic index 0.004 0.002 0.006 0.003 0.179 0.003 0.001 0.005 0.001 0.134
AUC C-peptide/AUC glucose 0.002 0.001 0.002 0.000 0.165 0.003 0.001 0.003 0.001 0.128
BMI (kg/m2) 27.1 2.3 27.0 2.7 0.79 20.3 1.5 20.3 1.6 0.89
LogMAR 0.8 0.2 0.9 0.2 0.76 0.6 0.2 0.6 0.2 0.85
WURS 20.5 2.8 18.6 4.5 0.72 21.3 6.4 18.4 5.7 0.74
WURS (physician rated) 7.6 1.8 8.8 2.7 0.71 3.1 1.3 3.1 1.2 1.00
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Contrasting these populations, subjects with Wolfram syndrome tend to have much higher C-peptide com-
pared with type 1 diabetes. Notably the preserved C-peptide group in the 2019 study had a mean stimulated 
C-peptide of 114 pmol/L (0.3443 ng/mL). This is compared with a mean stimulated C-peptide of 0.52 ng/mL 
(205 pmol/L) in our study population with Wolfram syndrome. These data suggest that small, but statistically 
insignificant, increases in C-peptide may be clinically significant. We suggest that future studies of dantrolene 
or similar agents track changes in total daily insulin dose (with percentage basal versus bolus) and analyze con-
tinuous glucose monitor tracings (i.e., time in range, time in hypoglycemia, and standard deviation).
As previously reported, markers of  inflammatory cytokines and oxidative stress, such as IFN-γ, IL-1β, 
TNF-α, and isoprostane, were elevated in subjects with Wolfram syndrome (31–33, 35). Biomarkers for 
neurodegeneration, such as neurofilament light chain and myelin basic protein, have been assessed in 
patients with Wolfram syndrome before (31, 40). Further studies on such biomarkers and their relation-
ships in phenotypes of  patients will lead to an identification of  surrogate biomarkers for clinical outcomes 
in patients with Wolfram syndrome.
We postulate that efficacy of  dantrolene may be linked to the nature of  the WFS1 mutations in the 
individual subjects. Over time, and with further experience with dantrolene, perhaps dantrolene can be part 
of  a personalized medicine approach for patients with Wolfram syndrome.
In summary, this study suggests that dantrolene sodium is safely tolerated by subjects with Wolfram 
syndrome. Although the study was small, a select few subjects seemed to have improvements in β cell 
function. Therefore, this study justifies further investigation into using dantrolene sodium and other new 
medications targeting ER stress for the treatment of  Wolfram syndrome.
Methods
Study protocol. Dantrolene sodium was dispensed to the study subjects via Washington University’s clinical 
trials pharmacy. Subjects were instructed to take the dantrolene by mouth. Subjects enrolled in this study 
underwent a run-in period for dose maximization (Figure 1A). Adult subjects were started on up to 25 mg 
dantrolene daily for 7 days, then doubled in dose on a weekly basis up to a maximum of  200 mg dantro-
lene daily. Pediatric subjects (<18 years old) were started on up to 0.5 mg/kg dantrolene daily (maximum 
25 mg) for 7 days, then doubled in dose on a weekly basis up to a maximum of  2 mg/kg dantrolene daily 
(maximum 200 mg), with no dose change if  weight fell within ±3% of  the original dosing weight. Dosing 
calendars were maintained by the study subjects to ensure adherence to the study drug.
Safety assessment and outcomes measures. Baseline screening procedures included complete physical exam, 
standard clinical laboratory tests (serum chemistry, liver function tests, hematology, and urinalysis), and 
12-lead ECG. Subjects underwent formal visual acuity testing by the coauthors of  the study who are either 
optometrists or ophthalmologists. At baseline, each subject underwent the WURS (30). The 30-minute 
Figure 2. Subgroup analysis to determine responders versus nonresponders. (A) ΔC-peptide was plotted between all subjects. Then the change in 
ΔC-peptide (ΔΔC-peptide) was calculated for each subject over the course of the study. Subjects were stratified based on a ΔΔC-peptide < 0.05, 0.05–0.1, 
and ≥ 0.1 ng/mL, respectively. (B) Linear regression analysis demonstrates a significant positive relationship between baseline ΔC-peptide and ΔΔC- 
peptide. Statistical significance was determined by the ordinary least squares method.
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MMTT was performed to assess baseline β cell functions as described before (24). The mixed meal consisted 
of  6 mL/kg (maximum 360 mL) of  Boost (Nestle) consumed over a maximum of 5 minutes. After the over-
night fasting, blood for glucose and C-peptide measurement was drawn at time 0 (fasting) and 30 minutes 
after the Boost. If  a subject’s fasting glucose exceeded 250 mg/dL, the test was not performed, but fasting glu-
cose and C-peptide were obtained. An ECG was performed before and 4 hours after the first dose of  dantro-
lene was administered during the run-in period, then again at 2 months and 6 months. Best-corrected visual 
acuity was assessed by Snellen optotype and converted to LogMAR score (41). Vision-related quality of  life 
was assessed in all subjects at screening and after 6 months of  dantrolene by the NEI VFQ-25 (42). Func-
tional activities of  daily living were assessed in pediatric subjects by the PedsQL (https://www.pedsql.org/) 
(43), while the SF-36v2 (https://www.optum.com/) was used to measure self-reported functional health and 
well-being of  adults at baseline and after 6 months of  dantrolene therapy (44). If  no safety concerns were 
identified at screening, subjects began the 3-week dose maximization period of  dantrolene sodium. All base-
line screening procedures were repeated again at 6 months of  treatment to ensure subject safety and assess 
dantrolene tolerability. Grip strength was measured at each visit bilaterally using a digital hand dynamometer 
(CAMRY). A final safety follow-up visit was conducted at 28 days (±7 days) after the last outcome measure 
evaluation in order to collect additional information on adverse events, concomitant medications, therapies, 
and procedures. For subjects who discontinued the study prior to the first outcome measure evaluation, safety 
follow-up visit was conducted within 28 days (±7 days) after the last administration of  dantrolene sodium.
Labs and biomarker levels. Comprehensive metabolic panel, HbA1c, C-peptide, and complete blood 
count (CBC) were performed by the Core Laboratory for Clinical Studies at Washington University in St. 
Louis. This is a Clinical Laboratory Improvement Amendments–certified and College of  American Pathol-
ogists–accredited laboratory. The CMP and HbA1c were performed on a Roche c501 automated analyzer 
with commercially available kits from Roche. Specifically, HbA1c used the Tina Quant, Gen 3 assay. The 
C-peptide was performed on Roche’s e601 automated analyzer, which uses a sandwich electrochemilumi-
nescence immunoassay. The precision, as measured by coefficient of  variation (CV; %) of  these assays, is 
between 1.2% and 3.8%. CBC was performed on the Beckman Coulter UniCell DxH600, an automated 
hematology analyzer. Ammonia, urine human chorionic gonadotropin, serum osmolality, and urine anal-
ysis were sent to Quest Laboratories for testing.
Inflammatory cytokine levels were assessed at the immune-monitoring laboratory at Washington 
University. The MILLIPLEX MAP Human High Sensitivity T Cell Magnetic Bead Panel (HSTCMAG-
28SMPX21; MilliporeSigma) simultaneously measures 21 analytes (fractalkine, GM-CSF, IFN-γ, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12p70, IL-13, IL-17A, IL-21, IL-23, ITAC, MIP-1α, MIP-1β, 
MIP-3α, and TNF-α) using a magnetic bead–based fluorescence sandwich ELISA. Samples were thawed 
on ice, centrifuged at 15,000 RCF for 5 minutes to remove particulates, and then added in duplicate wells 
to prepared beads, according to the manufacturer’s protocol. A Luminex FLEXMAP3D instrument was 
used to collect and measure the MFI of  50 beads per analyte per well. The assay contained recombinant 
protein standards for each analyte and a quality control (QC) sample. The interassay precision was assessed 
by percentage recovery of  each standard analyte, percentage CV of  replicate wells, and percentage recov-
ery of  the QC sample. Percentage recoveries were within 75%–120% of  the expected concentration for all 
analytes and the QC. The percentage CV of  replicates was less than 25% and generally less than 10% for 
most samples. A 5-parameter logistic function with 1/y2 weighting was fit using Belysa v.1 analysis software 
(MilliporeSigma). The lower limit of  quantitation was defined by the software for each analyte.
F2-isoprostanes were analyzed in the Eicosanoid Core Laboratory at Vanderbilt University Medical Cen-
ter. For analysis, 1 mL plasma was diluted to a volume of  10 mL by the addition of  0.01N HCl. The internal 
standard (1.0 ng, [2H4]-15-F2t-IsoP) was added, and the solution was adjusted to pH 3 with 1N HCl. The sam-
ple was then applied to a C-18 Sep-Pak cartridge (Waters) that had been prewashed with 5 mL methanol and 
5 mL 0.01N HCl. The cartridge was washed with 10 mL 0.01N HCl, followed by 10 mL heptane, and com-
pounds were then eluted with 10 mL ethyl acetate/heptane (50:50, v/v). The eluate was dried under nitrogen. 
Figure 3. Secondary study endpoints. (A) C-peptide during an MMTT. Light boxes represent fasting results, while dark boxes represent 30-minute (stimu-
lated) values. (B) LogMAR (a measure of visual acuity). Lower score correlates to more accurate vision. (C) WURS score. (D) Physician-rated subsection of the 
WURS. Higher WURS scores represent more severe disease. All study subjects are broken down into adult and pediatric subgroups. Responders are differenti-
ated from nonresponders by having a change in ΔC-peptide (ΔΔC-peptide) ≥ 0.1 ng/mL over the study period. The box shows the quartiles of the data set while 
the whiskers extend to show the rest of the distribution. Paired analyses among the same group (i.e., adult or pediatric) were performed using the Wilcoxon 
signed-rank test. The Mann-Whitney U test was used when comparing between groups (adult vs. pediatric subjects or nonresponders vs. responders).
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Analytes were converted to the pentafluorobenzyl (PFB) esters by the addition of  40 μL of a 10% solution of  
pentafluorobenzyl bromide in acetonitrile and 20 μL of a solution of  10% N,N-Diisopropylethylamine in ace-
tonitrile and allowed to incubate for 30 minutes at 37°C. Reagents were dried under nitrogen and the residue 
was reconstituted in 30 μL chloroform and 20 μL methanol and chromatographed on a silica TLC plate to 
13 cm in a solvent system of chloroform/methanol (93:7, v/v). The methyl ester of  PGF2α was chromato-
graphed on a separate lane and visualized with 10% phosphomolybdic acid in ethanol by heating. The Rf of  
PGF2α methyl ester in this solvent system is 0.15. Compounds migrating in the region 1 cm below the PGF2α 
standard to 1.0 cm above the standard were scraped from the TLC plate, extracted with 1 mL ethyl acetate/
ethanol (85:15, v/v), and dried under nitrogen. Following TLC purification, compounds were converted to 
trimethylsilyl (TMS) ether derivatives by addition of  20 μL N,O-bis(trimethylsilyl)trifluoroacetamide and 10 
μL dimethylformamide. The sample was incubated at 37°C for 10 minutes and then dried under nitrogen. The 
residue was dissolved for gas chromatography/mass spectrometry (GC/MS) analysis in 20 μL undecane that 
had been stored over a bed of  calcium hydride. GC/negative ion chemical ionization–MS (GC/NICI-MS) 
was carried out on an Agilent 5973 Inert Mass Selective Detector that was coupled with an Agilent 6890n 
Network GC system that is interfaced with an Agilent computer. GC was performed using a 15 m, 0.25 μm 
film thickness, with DB-1701 fused silica capillary column (J and W Scientific). The column temperature was 
programmed from 190°C to 300°C at 20°C per minute. The major ion generated in the NICI mass spectrum 
of the PFB ester, TMS ether derivative of  F2-IsoPs, was the m/z 569 carboxylate anion [M-181 (M-CH2C6F5)]. 
The corresponding ion generated by the [2H4]-15-F2t-IsoP internal standard was m/z 573. Levels of  endoge-
nous F2-IsoPs in a biological sample are calculated from the ratio of  intensities of  the ions m/z 569 to m/z 
573. Employing this assay, the lower limit of  detection of  F2-IsoPs is 4 pg using an internal standard with a 
blank of  3 parts per thousand. The precision of  this assay in biological fluids is +6% and the accuracy 94%. 
The normal range of  F2-IsoPs in plasma is 35 ± 6 pg/μL (34–36).
Statistics. Secondary outcome measures (C-peptide, LogMAR, WURS, HbA1c, BMI, glucose, proinsulin, 
insulinogenic index, AUC C-peptide/AUC glucose, proinsulin/C-peptide) were reported as the median and 
interquartile range. When analyzing differences among the same group (all subjects, adult, pediatric, nonre-
sponders, and responders) at 0 and 6 months, we used the Wilcoxon signed-rank test, using SciPy (https://
www.scipy.org) and pandas (https://pandas.pydata.org/index.html) programming libraries. Subjects who 
dropped out of  the study or who did not complete a secondary outcome measure were excluded from these 
analyses. Subject 12 had a LogMAR of 3 (functionally blind); therefore, this subject’s LogMAR score was 
excluded from the analysis. The Mann-Whitney U test was used when comparing between groups (adult vs. 
pediatric subjects or nonresponders vs. responders), also using SciPy and pandas programming libraries. Lin-
ear regression analyses (including R2 and P values) were constructed using the ordinary least squares method 
Table 5. Secondary study endpoints for nonresponders and responders
Class Nonresponders Responders
Duration (months) 0 SEM 6 SEM P value 0 SEM 6 SEM P value
HbA1c (%) 7.5 0.2 7.6 0.3 0.82 7.1 0.2 7.1 0.3 0.91
Fasting glucose (mg/dL) 149.9 11.1 148.0 20.1 0.93 135.8 18.5 203.2 20.4 0.04
Stimulated glucose (mg/dL) 257.0 10.8 253.4 17.8 0.86 213.2 30.0 286.8 13.6 0.06
ΔGlucose (mg/dL) 0.39 0.06 0.38 0.05 0.91 0.80 0.27 1.20 0.33 0.38
Fasting C-peptide (ng/mL) 0.18 0.03 0.15 0.03 0.56 0.47 0.17 0.53 0.17 0.79
Stimulated C-peptide (ng/mL) 0.39 0.06 0.38 0.05 0.91 0.80 0.27 1.20 0.33 0.36
ΔC-peptide (ng/mL) 0.21 0.03 0.23 0.02 0.66 0.33 0.11 0.67 0.17 0.14
Fasting proinsulin (pmol/L) 0.7 0.2 0.6 0.1 0.21 0.8 0.1 2.0 0.7 0.31
Stimulated proinsulin (pmol/L) 1.3 0.6 1.1 0.4 0.86 2.2 0.6 6.3 2.2 0.25
ΔProinsulin (pmol/L) 0.5 0.4 0.6 0.4 0.87 1.4 0.5 4.3 1.6 0.25
Insulinogenic index 0.002 0.000 0.002 0.000 0.669 0.006 0.003 0.012 0.005 0.128
AUC C-peptide/AUC glucose 0.001 0.000 0.001 0.000 0.492 0.003 0.001 0.004 0.001 0.388
BMI (kg/m2) 25.4 2.0 25.2 2.4 0.61 21.5 2.3 21.3 2.4 0.70
LogMAR 0.7 0.2 0.8 0.2 0.87 0.8 0.2 0.7 0.3 0.95
WURS 23.1 3.7 21.0 4.3 0.70 13.8 2.8 11.6 3.9 0.66
WURS (physician rated) 6.3 1.6 7.5 2.3 0.67 4.2 1.6 3.2 1.2 0.62
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using the statsmodels (https://www.statsmodels.org/devel/about.html#about-statsmodels) programming 
library. A P < 0.05 was considered significant for all analyses. Figures were constructed with matplotlib 
(https://matplotlib.org) and seaborn (https://seaborn.pydata.org) programming libraries or GraphPad Prism 
8 software (https://www.graphpad.com/scientific-software/prism/). Receiver operator characteristic curves 
and calculations were constructed using GraphPad Prism 8 software.
Study approval. Subjects, and their parent or legal guardian, as appropriate, provided written, informed 
consent before participating in this study, which was approved by the Human Research Protection Office at 
Washington University School of  Medicine in St. Louis (IRB ID #201607006).
Subjects who met all of  the following criteria were eligible for enrollment: first, a definitive diagno-
sis of  Wolfram syndrome, as determined by the following: a) documented functionally relevant recessive 
mutations on both alleles of  the WFS1 gene or b) a dominant mutation on 1 allele of  the WFS1 gene based 
on historical test results (if  available) or from a qualified laboratory at screening; second, the subject was 
at least 5 years of  age (biological age) at the time of  written informed consent; and third, the subject, sub-
ject’s parent(s), or legally authorized guardian(s) must have voluntarily signed an IRB/Independent Ethics 
Committee-approved informed consent form after all relevant aspects of  the study have been explained and 
discussed with the subject. The guardians’ consent and subjects’ assent, as relevant, were obtained.
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